Conversely, the FNR of SLNB was higher than the acceptable value of 10% in HER2+ or TNBC breast cancer with non-complete MRI response and in HR+ HER2− breast cancer, regardless of treatment response. This evidence concerns the gene ERBB2 and breast carcinoma.